Clinical Trials Browser

Phase 3 × Fibroblast Growth Factor 7 × Other hematologic neoplasm × Clear all

NCT00109031 2014-09-15

Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)

Phase 3 Completed

47 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms